Compare Boston Scientific Corporation (BSX) vs Trade Desk Inc (TTD) Price & Performance

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

The Trade Desk (TTD) is trading at $13.80, down 21.9% in 24 hours and near 7-year lows following disappointing Q2 earnings. Revenue grew just 3% to $715 million, missing guidance, while Q3 guidance projects a 12% decline. Technical indicators show bearish momentum with support at $13 and resistance at $15. Despite strong profitability metrics including 76.9% gross margins, recent execution gaps and advertiser pressure have triggered multiple analyst downgrades.

The outlook remains challenging with near-term revenue headwinds and competitive pressures. While valuation appears reasonable at 16.4x P/E, the stock faces significant execution risks and sentiment deterioration. Recovery depends on stabilizing advertiser relationships and reversing recent market share losses in the ad-tech sector.